Want to see IN:ROSSARI full AI Analyst Report?
Rossari Biotech Ltd (ROSSARI) AI Stock Analysis
Rossari Biotech Ltd
(NSE:ROSSARI)
The score is primarily supported by strong revenue growth, stable profitability, and a positive earnings outlook. Weak cash conversion is the largest fundamental risk, while mixed technical momentum and a minimal dividend yield limit the upside.
Rossari Biotech Ltd (ROSSARI) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 22.12B
- Dividend Yield
- 0.13%
- Average Volume (3M)
- 4,479
- Price to Earnings (P/E)
- 14.5
- Beta (1Y)
- 1.15
- Revenue Growth
- 19.76%
- EPS Growth
- 11.74%
- Country
- India
- Employees
- 585
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Rossari Biotech Ltd Business Overview & Revenue Model
Company Description
Rossari Biotech Limited, an India-based company, is a global manufacturer and distributor of specialized chemical products. Its diverse offerings cater to numerous industries, including ingredients for soaps and detergents, formulations for inks, pai...
How the Company Makes Money
Rossari Biotech makes money primarily by selling specialty chemical formulations and allied solutions to business customers (B2B). Its revenue model is driven by: (1) Product sales across application categories: The company supplies textile specialty...
Rossari Biotech Ltd Earnings Call Summary
The call was broadly positive, supported by record quarterly revenue and EBITDA, strong growth across all three divisions, accelerating exports, improved working capital, debt reduction, and progress in higher-value products and international expansion. However, management highlighted meaningful near-term challenges from raw material volatility, freight and geopolitical disruption, ethylene oxide availability, lower core B2B margins, modest B2C revenue growth, and uncertainty around second-half demand and the Saudi project timeline.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects exports to reach “at least 30% plus” of revenue by the end of this year, B2C and institutional EBITDA to be positive in “H2 second half” and to “at least break even” on a full-year basis, FY 2027 EBITDA to be “around 12% plus minus,” and full-year revenue growth to be “between mid-teen to a little high teen numbers.” Peak utilization of the approximately 50,000 ton ethoxylation capacity is expected “about two years” after commissioning, with peak sales revenue of “3X of the CapEx value” by the end of FY 2028; Reliance’s EO expansion is expected in the “first quarter of next financial year,” although “there is no confirmation” on incremental quantities. The company expects working-capital debt to become debt-free “by mid of next year,” working capital to remain within “87 to 90 days,” and some Saudi Arabia developments to occur over the next “8 to 12 months,” while significant EBITDA percentage and ROCE improvements are expected “next year.”
Rossari Biotech Ltd Financial Statement Overview
Summary
Revenue growth and stable profitability support the score, while manageable leverage is offset by weak and erratic cash generation. Income Statement: 82, Balance Sheet: 75, Cash Flow: 45.
Income Statement
82Very PositiveBalance Sheet
75PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.61B | 23.96B | 20.80B | 18.31B | 16.56B | 14.83B |
| Gross Profit | 6.74B | 4.94B | 6.47B | 5.26B | 2.80B | 2.29B |
| EBITDA | 3.08B | 2.86B | 2.65B | 2.57B | 2.12B | 1.94B |
| Net Income | 1.53B | 1.49B | 1.36B | 1.31B | 1.07B | 976.74M |
Balance Sheet | ||||||
| Total Assets | 23.59B | 22.89B | 18.96B | 15.72B | 13.68B | 12.57B |
| Cash, Cash Equivalents and Short-Term Investments | 1.14B | 1.27B | 1.14B | 667.85M | 1.52B | 644.26M |
| Total Debt | 3.88B | 4.36B | 2.18B | 1.19B | 739.28M | 84.27M |
| Total Liabilities | 9.52B | 9.55B | 7.11B | 5.24B | 4.52B | 4.52B |
| Stockholders Equity | 14.08B | 13.33B | 11.85B | 10.48B | 9.15B | 8.05B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -2.20B | -210.69M | -880.28M | 1.20B | -88.67M |
| Operating Cash Flow | 0 | 451.63M | 1.37B | 432.55M | 1.52B | 293.58M |
| Investing Cash Flow | 0 | -2.22B | -1.84B | -1.03B | -1.81B | -2.99B |
| Financing Cash Flow | 0 | 2.09B | 649.01M | 161.85M | 608.55M | 2.92B |
Rossari Biotech Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Negative. The current price of 399.25 is below the 20-day moving average (MA) of 421.62, below the 50-day MA of 446.42, and below the 200-day MA of 489.54, indicating a bearish trend. The MACD of -11.02 indicates Positive momentum. The RSI at 35.38 is Neutral, neither overbought nor oversold. The STOCH value of 11.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ROSSARI.
Rossari Biotech Ltd Peers Comparison
Overall Rating
IN:KIRIINDUS77Outperform
IN:FCL69Neutral- IN:ROSSARI65Neutral
IN:GALAXYSURF59Neutral
IN:BALAMINES57.5Neutral
IN:TATVA55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:KIRIINDUS | 77Outperform | INR 35.17B | 0.56 | ― | ― | 10.71% | 2756.39% |
| IN:FCL | 69Neutral | INR 56.58B | 40.33 | ― | 0.27% | 91.44% | 19.67% |
| IN:ROSSARI | 65Neutral | INR 22.12B | 14.48 | ― | 0.13% | 19.76% | 11.74% |
| IN:GALAXYSURF | 59Neutral | INR 75.16B | 21.20 | ― | 1.04% | 27.05% | 16.13% |
| IN:BALAMINES | 58Neutral | INR 57.16B | 27.90 | ― | 0.63% | 11.08% | 34.10% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:TATVA | 55Neutral | INR 38.49B | 61.11 | ― | 0.12% | 49.69% | 254.75% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ROSSARI | Rossari Biotech Ltd | 399.25 | -242.58 | -37.79% | |
| IN:BALAMINES | Balaji Amines Limited | 1764.15 | 351.10 | 24.85% | |
| IN:FCL | Fineotex Chemical Limited | 48.59 | 16.55 | 51.67% | |
| IN:GALAXYSURF | Galaxy Surfactants Ltd. | 2119.80 | -117.93 | -5.27% | |
| IN:KIRIINDUS | Kiri Industries Limited | 539.70 | -6.25 | -1.14% | |
| IN:TATVA | Tatva Chintan Pharma Chem Limited | 1645.45 | 235.40 | 16.69% |
Rossari Biotech Ltd Corporate Events
Rossari Biotech Releases Q2 and H1 FY27 Earnings Presentation
Rossari Biotech Limited operates in the specialty chemicals sector, providing diversified chemical solutions for various industrial applications. The company is listed on both BSE and the National Stock Exchange of India, indicating a broad investor...
Rossari Biotech Delivers Record Q2 Results and Plans Saudi Expansion
Rossari Biotech reported its highest-ever quarterly revenue of Rs. 697.6 crore and EBITDA of Rs. 87 crore in Q2 FY27, driven by strong export sales and improved working capital efficiency, though profit after tax remained subdued at Rs. 38.9 crore du...
Rossari Biotech Publishes Unaudited September 2026 Consolidated Results in Newspapers
Rossari Biotech Ltd has published in Financial Express and Loksatta an extract of its consolidated unaudited financial results for the quarter and half year ended 30 September 2026, in line with disclosure obligations under SEBI’s Listing Regul...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 19, 2026